CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗消化系统恶性肿瘤的进展与挑战
英文原题：Advances and challenges of chimeric antigen receptor T cell therapy in digestive system malignancies.
查看英文原题
Advances and challenges of chimeric antigen receptor T cell therapy in digestive system malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞疗法（CAR-T）已彻底改变了血液系统恶性肿瘤的治疗格局，但其在实体瘤尤其是消化系统肿瘤中的成功仍然有限。胃肠道系统肿瘤，包括胃、结直肠、食管、肝脏和胰腺恶性肿瘤，构成了重大的全球健康负担，具有高发病率和死亡率。近年来在抗原选择、嵌合抗原受体设计、递送技术和联合治疗策略方面的进展，重新激发了人们对CAR-T 免疫疗法用于这些癌症的兴趣。本文讨论了CAR-T 在主要消化系统肿瘤中开发的最新进展，概述了肿瘤特异性靶点和临床试验，强调了当前面临的挑战和潜在解决方案，并提出了实体瘤下一代CAR-T 疗法的战略方向。
展开英文摘要原文
Chimeric antigen receptor T cell therapy (CAR-T) has revolutionized the treatment of hematologic malignancies, but its success in solid tumors, particularly those of the digestive system, remains limited. Tumors of the gastrointestinal system, including gastric, colorectal, esophageal, hepatic, and pancreatic malignancies, represent a significant global health burden with high morbidity and mortality.
Recent advances in antigen selection, chimeric antigen receptor design, delivery techniques, and combinatorial approaches have sparked renewed interest in CAR-T immunotherapy for these cancers. This article discusses recent progress in CAR-T development across the major digestive system tumors, outlines tumor-specific targets and clinical trials, highlights prevailing challenges and potential solutions, and proposes strategic directions for the next generation of CAR-T therapies in solid tumors.
论文信息
- 作者
- Wang C、Zhang J、Chen ZK、Wang YG、Shi M
- 第一作者单位
- Department of Gastroenterology, Shanghai Tong Ren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China.China
- 通讯作者单位
- Department of Gastroenterology, Shanghai Tong Ren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China. sm1790@shtrhospital.com.China
- 文献类型
- 综述
- 期刊
- World journal of clinical oncology2026 Feb 24
- 原文标识
- PubMed 41810338 · DOI 10.5306/wjco.v17.i2.114107
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →